17 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
).
oEssential3 has over 3,000 referrals who have met the pre-qualifying eligibility criteria from the ongoing recruitment campaign started in November 2023
8-K
EX-99.2
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
TETRAS ADL* scale
11 Alignment with FDA on dose and primary endpoint Phase 3 program design structured around the patient needs Robust recruitment
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
patients engaged in pre-recruitment observational study
Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development … mg dose of ulixacaltamide for up to 12 weeks after a short titration period. In September 2023, Praxis initiated a pre-recruitment observational
8-K
EX-99.1
b3p9tym4azy8nd
16 Aug 21
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8:04am
DEF 14A
oiqj1
29 Apr 21
Definitive proxy
4:04pm
10-K
duga7b20juy
17 Mar 21
Annual report
8:33am
10-Q
driq2mj16hzpnc saw1
23 Nov 20
Quarterly report
4:16pm
424B4
uz0c3b l43tw1e
16 Oct 20
Prospectus supplement with pricing info
4:02pm
S-1/A
uvqc6 clwbug
9 Oct 20
IPO registration (amended)
6:09am
S-1
aysaqx
25 Sep 20
IPO registration
5:19pm
DRS/A
6h73mj
28 Aug 20
Draft registration statement (amended)
12:00am
DRS
fgm7wrstnzyx50dj53tn
22 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next